Cytel brings together Quantitative, Computational, Regulatory, and Strategic Drug Development Capabilities into Modern Therapeutics Development Team
WALTHAM MASSACHUSETTS – Cytel Inc., a leading provider of innovative statistics and health data analytics to the life sciences industry, has advanced its strategic drug development capabilities with a new Therapeutics Development Team (TDT). The TDT combines Cytel’s heritage of pioneering strategies such as adaptive trial design with best-in-class tools like the award-winning Solara® platform for simulation guided trial design, and a broadened client interface emphasizing an integrated and quantitative approach to essential disciplines, including clinical development, regulatory affairs, and clinical pharmacology.
“As pioneers of biostatistics and decision sciences in the pharmaceutical space, creating the Therapeutics Development Team was the natural next step,” said Cytel CEO Joshua Schultz. “It enables us to combine these strengths with our regulatory knowledge to create robust designs and scalable solutions from clinical to commercialization.”
By combining advanced computational power with statistical methods, the TDT helps sponsors navigate clinical trial decision milestones and uncertainties, delivering strategic roadmaps for successful clinical trial outcomes. The TDT includes accomplished colleagues with senior-level experience at several top pharma companies, the FDA, and numerous small and large biotechnology sponsors, enabling authentic connections with clients of all sizes and stages of development.
Albert Kim, Cytel’s Chief Medical Officer, and Peter Russell, Senior Vice President, lead Cytel’s Therapeutics Development Team. Russell says, “We are uniquely positioned as a strategic partner for biopharma and biotech, bringing our talented colleagues and differentiated tools to any sponsor looking for a quantitative advantage in developing a new therapeutic, whether drug or device.”
Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution. For over thirty-five years, Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove value and make confident, evidence-based decisions. Its experts deliver industry-leading software, data-driven analytics, real-world evidence and strategic consulting. Headquartered in Waltham, Massachusetts, Cytel has more than 2,000 employees across North America, Europe and Asia. For more information about Cytel, please visit us at www.cytel.com.